Correlation Between Abcellera Biologics and Y MAbs

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Abcellera Biologics and Y MAbs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abcellera Biologics and Y MAbs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Abcellera Biologics and Y mAbs Therapeutics, you can compare the effects of market volatilities on Abcellera Biologics and Y MAbs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abcellera Biologics with a short position of Y MAbs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abcellera Biologics and Y MAbs.

Diversification Opportunities for Abcellera Biologics and Y MAbs

-0.3
  Correlation Coefficient

Very good diversification

The 3 months correlation between Abcellera and YMAB is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Abcellera Biologics and Y mAbs Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Y mAbs Therapeutics and Abcellera Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abcellera Biologics are associated (or correlated) with Y MAbs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Y mAbs Therapeutics has no effect on the direction of Abcellera Biologics i.e., Abcellera Biologics and Y MAbs go up and down completely randomly.

Pair Corralation between Abcellera Biologics and Y MAbs

Given the investment horizon of 90 days Abcellera Biologics is expected to under-perform the Y MAbs. In addition to that, Abcellera Biologics is 1.41 times more volatile than Y mAbs Therapeutics. It trades about -0.23 of its total potential returns per unit of risk. Y mAbs Therapeutics is currently generating about -0.22 per unit of volatility. If you would invest  580.00  in Y mAbs Therapeutics on December 4, 2024 and sell it today you would lose (95.00) from holding Y mAbs Therapeutics or give up 16.38% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy95.24%
ValuesDaily Returns

Abcellera Biologics  vs.  Y mAbs Therapeutics

 Performance 
       Timeline  
Abcellera Biologics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Abcellera Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Y mAbs Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Y mAbs Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Abcellera Biologics and Y MAbs Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Abcellera Biologics and Y MAbs

The main advantage of trading using opposite Abcellera Biologics and Y MAbs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abcellera Biologics position performs unexpectedly, Y MAbs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Y MAbs will offset losses from the drop in Y MAbs' long position.
The idea behind Abcellera Biologics and Y mAbs Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk